Tammy Leitsinger - Silk Road Compliance Affairs
| SILK Stock | USD 18.90 1.10 6.18% |
Insider
Tammy Leitsinger is Compliance Affairs of Silk Road Medical
| Address | 1213 Innsbruck Drive, Sunnyvale, CA, United States, 94089 |
| Phone | 408 720 9002 |
| Web | https://silkroadmed.com |
Silk Road Management Efficiency
The company has return on total asset (ROA) of (0.1385) % which means that it has lost $0.1385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3539) %, meaning that it created substantial loss on money invested by shareholders. Silk Road's management efficiency ratios could be used to measure how well Silk Road manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.22. The value of Return On Capital Employed is expected to slide to -0.26. The value of Total Current Liabilities is estimated to slide to about 20.6 M. The value of Liabilities And Stockholders Equity is expected to slide to about 171.6 MSimilar Executives
| Showing other executives | INSIDER Age | ||
| Andrew Honeybone | Acadia Healthcare | N/A | |
| John Gochnour | Pennant Group | 41 | |
| Yitao Zhou | Aesthetic Medical Intl | 45 | |
| Michael McAlevey | HCA Holdings | 60 | |
| FACHE MBA | Novo Integrated Sciences | N/A | |
| Jennifer CPA | Pennant Group | 55 | |
| Christopher Hunter | Acadia Healthcare | 56 | |
| Laurence Harrod | Acadia Healthcare | 67 | |
| Sammie Mosier | HCA Holdings | N/A | |
| BScBio BScPT | Novo Integrated Sciences | N/A | |
| Derrick Shi | Aesthetic Medical Intl | N/A | |
| Andrea Smith | HCA Holdings | 54 | |
| Indrajit Sinha | Novo Integrated Sciences | N/A | |
| James Zsebok | Novo Integrated Sciences | 58 | |
| Jennifer Berres | HCA Holdings | 53 | |
| J Morrow | HCA Holdings | 50 | |
| MD JD | Acadia Healthcare | N/A | |
| Guanhua Wu | Aesthetic Medical Intl | 41 | |
| Ding Wenting | Aesthetic Medical Intl | 59 | |
| Hugh Johnston | HCA Holdings | 59 | |
| David CFA | Acadia Healthcare | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.14 |
Silk Road Medical Leadership Team
Elected by the shareholders, the Silk Road's board of directors comprises two types of representatives: Silk Road inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silk. The board's role is to monitor Silk Road's management team and ensure that shareholders' interests are well served. Silk Road's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silk Road's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erica Rogers, President CEO, Director | ||
| Sumaira Macdonald, Chief Medical Officer | ||
| Mhairi Jones, VP Accounting | ||
| Sumaira MD, Executive Director | ||
| Kevin Ballinger, Chief Sec | ||
| Tammy Leitsinger, Compliance Affairs | ||
| Kevin Klemz, Chief EVP | ||
| Alison Highlander, Vice Resources | ||
| Jorge OHara, Business Marketing | ||
| Mark Caires, Vice President - Finance & Administration | ||
| Charles McKhann, Chief Officer | ||
| Richard Ruedy, Executive Vice President - Regulatory Affairs, Clinical Affairs & Quality Assurance | ||
| Lucas Buchanan, CFO COO | ||
| Lynn Lewis, Investors Officer | ||
| Andrew Davis, Chief Officer | ||
| Matthew McCarthy, Vice Marketing |
Silk Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silk Road a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 600.47 M | ||||
| Shares Outstanding | 39.17 M | ||||
| Shares Owned By Insiders | 5.93 % | ||||
| Shares Owned By Institutions | 94.07 % | ||||
| Number Of Shares Shorted | 4.14 M | ||||
| Price To Book | 4.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Silk Road in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Silk Road's short interest history, or implied volatility extrapolated from Silk Road options trading.
Currently Active Assets on Macroaxis
When determining whether Silk Road Medical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Silk Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Silk Road Medical Stock. Highlighted below are key reports to facilitate an investment decision about Silk Road Medical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silk Road Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Silk Stock analysis
When running Silk Road's price analysis, check to measure Silk Road's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silk Road is operating at the current time. Most of Silk Road's value examination focuses on studying past and present price action to predict the probability of Silk Road's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silk Road's price. Additionally, you may evaluate how the addition of Silk Road to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Silk Road's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silk Road. If investors know Silk will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silk Road listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Revenue Per Share 4.565 | Quarterly Revenue Growth 0.18 | Return On Assets (0.14) | Return On Equity (0.35) |
The market value of Silk Road Medical is measured differently than its book value, which is the value of Silk that is recorded on the company's balance sheet. Investors also form their own opinion of Silk Road's value that differs from its market value or its book value, called intrinsic value, which is Silk Road's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silk Road's market value can be influenced by many factors that don't directly affect Silk Road's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silk Road's value and its price as these two are different measures arrived at by different means. Investors typically determine if Silk Road is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silk Road's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.